Seattle-based Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical firm that specializes in researching and developing protein-based immunotherapies to treat diseases such as cancer and autoimmune/inflammatory disorders. The company boasts a robust product pipeline with three programs that are undergoing development. ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program, targets autoimmune and inflammatory diseases. Meanwhile, ALPN-202 is a conditional CD28 costimulator and dual checkpoint inhibitor product that is designed for the treatment of cancer. Finally, ALPN-303 - a dual B cell cytokine antagonizing program - seeks to treat inflammatory and autoimmune diseases. This promising biopharmaceutical company has collaboration agreements with AbbVie Ireland Unlimited Company for the development of ALPN-101 and Adaptimmune Therapeutics PLC to produce next-generation SPEAR T cell products. The company's impressive 14-year journey began in 2007 when it was incorporated.
Alpine Immune Sciences's ticker is ALPN
The company's shares trade on the NASDAQ stock exchange
They are based in Seattle, Washington
There are 51-200 employees working at Alpine Immune Sciences
It is alpineimmunesciences.com
Alpine Immune Sciences is in the Healthcare sector
Alpine Immune Sciences is in the Biotechnology industry
The following five companies are Alpine Immune Sciences's industry peers: